North America Insulin Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers North America Insulin Pumps Market Share and It is Segmented Into Type (insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, and Jet Injectors) and Geography (Canada, United States, Rest of North America). The Market Provides the Value (in USD) and Volume (in Units) for the Above Segments.

North America Insulin Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

North America Insulin Delivery Devices Market Size

View Global Report
North America Insulin Delivery Devices Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
Market Size (2025) USD 15.33 Million
Market Size (2030) USD 19.62 Million
CAGR (2025 - 2030) 5.06 %

Major Players

North America Insulin Delivery Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of North America Insulin Delivery Devices Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

North America Insulin Delivery Devices Market Analysis

The North America Insulin Delivery Devices Market size is estimated at USD 15.33 million in 2025, and is expected to reach USD 19.62 million by 2030, at a CAGR of 5.06% during the forecast period (2025-2030).

The COVID-19 pandemic has substantially impacted the North America Insulin Delivery Devices Market. Type-1 diabetes patients are impacted more during COVID-19. People with diabetes are having a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes will have more chances to get into serious complications rather than normal people. The manufacturers of Insulin delivery devices have taken care during COVID-19 to deliver insulin delivery devices to diabetes patients with the help of local governments. Novo Nordisk stated on their website that 'Since the start of COVID-19, our commitment to patients, our employees and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.' Doctors around the world suggested diabetes patients should check their diabetes levels more often to be careful and the intake of medicine has increased, which lead to an increase in the usage of insulin delivery devices.

In North America, till April 2022, the United States had the highest number of COVID cases with 82 million, the country also registered the highest death rate. According to the Diabetes Voice, close to 40,000 people who died were having diabetes. In the North American region diabetes patients were more concerned about stocking up the monitoring and managing devices due to this the market increased during these years.

Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses compared to non-diabetic people. Patients with Type 2 diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates. Furthermore, patients attempting to control their blood glucose levels tightly to prevent the long-term complications associated with fluctuations in blood glucose levels are at greater risk for overcorrection and the resultant hypoglycemia. Achieving nominal results can be very difficult without multiple daily injections of insulin or insulin pump therapy.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

North America Insulin Delivery Devices Industry Overview

The North American insulin delivery devices market is moderately consolidated due to the presence of major players such as Novo Nordisk, Sanofi, Eli Lilly and Company, Medtronic, Insulet, Ypsomped, Becton Dickinson and Company, etc. operating globally and other regional players.

North America Insulin Delivery Devices Market Leaders

  1. Novo Nordisk

  2. Medtronic

  3. Sanofi

  4. Eli Lilly and Company

  5. Becton and Dickinson

  6. *Disclaimer: Major Players sorted in no particular order
North America Insulin Delivery Devices Market Comp..png
Need More Details on Market Players and Competiters?
Download PDF

North America Insulin Delivery Devices Market News

  • March 2023: Abbott announced that the U.S. Food and Drug Administration (FDA) cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems. Abbott modified the sensors to enable integration with AID systems.
  • October 2022: Becton Dickinson and Company and Biocorp announced that they signed an agreement to use connected technology to track adherence to self-administered drug therapies, like biologics. To support bio pharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies were expected to integrate Biocorp's Injay technology, a solution designed to capture and transmit injection events using Near Field Communication technology, with the BD UltraSafe Plus Passive Needle Guard used with prefillable syringes.

North America Insulin Delivery Devices Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Type
    • 5.1.1 Insulin Pumps
    • 5.1.1.1 Insulin Pump Device
    • 5.1.1.2 Insulin Pump Reservoir
    • 5.1.1.3 Infusion Set
    • 5.1.2 Insulin Syringes
    • 5.1.3 Cartridges in Reusable Pens
    • 5.1.4 Disposable Pens
    • 5.1.5 Jet Injectors
  • 5.2 Geography
    • 5.2.1 Canada
    • 5.2.2 United States
    • 5.2.3 Rest of North America

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Novo Nordisk AS
    • 7.1.2 Sanofi
    • 7.1.3 Eli Lilly and Company
    • 7.1.4 Medtronic PLC
    • 7.1.5 Insulet Corporation
    • 7.1.6 Ypsomed
    • 7.1.7 Becton Dickinson and Company
  • *List Not Exhaustive
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Novo Nordisk AS
    • 7.2.2 Sanofi
    • 7.2.3 Eli Lilly and Company
    • 7.2.4 Other Company Share Analyses

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*The report covers a segment-wise breakdown (Value and Volume) for all the countries covered under Table of Contents **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

North America Insulin Delivery Devices Industry Segmentation

There are different ways to inject insulin into a patient's body using syringes, pens, pumps, and jet injectors, giving them various options for insulin delivery. The North America insulin delivery devices market is segmented into type (insulin pumps, insulin syringes, cartridges in reusable pens, disposable pens, and jet injectors) and geography (Canada, United States, rest of North America). The report offers the value (in USD) and volume (in units) for the above segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.

Type Insulin Pumps Insulin Pump Device
Insulin Pump Reservoir
Infusion Set
Insulin Syringes
Cartridges in Reusable Pens
Disposable Pens
Jet Injectors
Geography Canada
United States
Rest of North America
Need A Different Region or Segment?
Customize Now

North America Insulin Delivery Devices Market Research FAQs

How big is the North America Insulin Delivery Devices Market?

The North America Insulin Delivery Devices Market size is expected to reach USD 15.33 million in 2025 and grow at a CAGR of 5.06% to reach USD 19.62 million by 2030.

What is the current North America Insulin Delivery Devices Market size?

In 2025, the North America Insulin Delivery Devices Market size is expected to reach USD 15.33 million.

Who are the key players in North America Insulin Delivery Devices Market?

Novo Nordisk, Medtronic, Sanofi, Eli Lilly and Company and Becton and Dickinson are the major companies operating in the North America Insulin Delivery Devices Market.

What years does this North America Insulin Delivery Devices Market cover, and what was the market size in 2024?

In 2024, the North America Insulin Delivery Devices Market size was estimated at USD 14.55 million. The report covers the North America Insulin Delivery Devices Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the North America Insulin Delivery Devices Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

North America Insulin Delivery Devices Industry Report

Statistics for the 2025 North America Insulin Delivery Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. North America Insulin Delivery Devices analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.